Experiment Protocol Biomedical Engineer in Netherlands Amsterdam –Free Word Template Download with AI

This Experiment Protocol outlines the procedures for evaluating a novel biomedical sensor designed for continuous glucose monitoring. The research is conducted by a team of Biomedical Engineers at the Academic Medical Center in Netherlands Amsterdam. The primary objective is to assess the accuracy, reliability, and safety of the sensor in a clinical setting, adhering to the stringent regulations and ethical standards of the Netherlands.

The main objectives of this experiment are:

• To evaluate the accuracy of the novel biomedical sensor in measuring blood glucose levels.
• To assess the sensor's reliability over a 72-hour period.
• To ensure the safety of the sensor for use in human subjects.
• To compare the performance of the novel sensor with existing commercial devices.

3.1 Study Design

This study will be a randomized, controlled trial involving 50 participants with type 1 diabetes. Participants will be randomly assigned to either the experimental group, using the novel biomedical sensor, or the control group, using a commercially available continuous glucose monitoring system.

3.2 Participant Selection

Participants will be recruited from the diabetes clinic at the Academic Medical Center in Netherlands Amsterdam. Inclusion criteria include:

• Age between 18 and 65 years.
• Diagnosed with type 1 diabetes for at least one year.
• Stable insulin regimen.
• Willingness to provide informed consent.

Exclusion criteria include:

• Pregnancy or breastfeeding.
• Severe renal or hepatic impairment.
• History of adverse reactions to similar devices.

3.3 Procedure

Upon enrollment, participants will undergo a baseline assessment, including a detailed medical history and physical examination. The biomedical sensor will be applied to the participant's abdomen by a trained Biomedical Engineer. Participants will be instructed to record their blood glucose levels using a standard glucometer at specified intervals for comparison.

Data will be collected continuously over a 72-hour period. Participants will be asked to maintain their usual diet and activity levels. Any adverse events will be recorded and reported immediately.

Data will be collected using a secure, encrypted database compliant with the General Data Protection Regulation (GDPR) of the European Union. The primary outcome measure will be the mean absolute relative difference (MARD) between the sensor readings and the reference glucometer values. Secondary outcomes include sensor accuracy in hypo- and hyperglycemic ranges, user satisfaction, and incidence of adverse events.

Statistical analysis will be performed using appropriate software, with a significance level set at p < 0.05. Results will be reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines.

This study has been approved by the Medical Ethics Committee of the Academic Medical Center in Netherlands Amsterdam. Informed consent will be obtained from all participants prior to enrollment. Participants will be informed of their right to withdraw from the study at any time without penalty. All data will be anonymized to protect participant confidentiality.

Safety is a paramount concern in this experiment. The biomedical sensor has undergone rigorous preclinical testing to ensure its safety for human use. Participants will be monitored closely for any adverse reactions, and a medical professional will be available at all times during the study period. In the event of a serious adverse event, the study will be paused, and the incident will be reported to the relevant authorities in the Netherlands.

This Experiment Protocol provides a comprehensive framework for evaluating the novel biomedical sensor in a clinical setting. By adhering to the highest standards of scientific rigor and ethical conduct, the research team aims to contribute valuable insights to the field of Biomedical Engineering and improve the quality of life for individuals with diabetes in Netherlands Amsterdam and beyond.